These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 31260162)
1. Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme. Mutthamsetty V; Dahal GP; Wang Q; Viola RE Chem Biol Drug Des; 2020 Jan; 95(1):48-57. PubMed ID: 31260162 [TBL] [Abstract][Full Text] [Related]
2. Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease. Thangavelu B; Mutthamsetty V; Wang Q; Viola RE Bioorg Med Chem; 2017 Feb; 25(3):870-885. PubMed ID: 28007430 [TBL] [Abstract][Full Text] [Related]
3. High Throughput Screening Cascade To Identify Human Aspartate Nešuta O; Thomas AG; Alt J; Hin N; Neužilová A; Long S; Tsukamoto T; Rojas C; Wei H; Slusher BS ACS Chem Neurosci; 2021 Sep; 12(18):3445-3455. PubMed ID: 34477360 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and Treatment of Canavan Disease. Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831 [No Abstract] [Full Text] [Related]
5. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
6. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
7. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
8. Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice. Hull V; Wang Y; Burns T; Zhang S; Sternbach S; McDonough J; Guo F; Pleasure D Ann Neurol; 2020 Mar; 87(3):480-485. PubMed ID: 31925837 [TBL] [Abstract][Full Text] [Related]
9. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease. Baslow MH; Suckow RF; Hungund BL J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430 [TBL] [Abstract][Full Text] [Related]
10. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model. Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021 [TBL] [Abstract][Full Text] [Related]
11. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859 [TBL] [Abstract][Full Text] [Related]
12. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
13. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461 [TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of aspartate N-acetyltransferase: A critical enzyme in brain metabolism. Wang Q; Zhao M; Parungao GG; Viola RE Protein Expr Purif; 2016 Mar; 119():11-8. PubMed ID: 26550943 [TBL] [Abstract][Full Text] [Related]
15. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Baslow MH; Guilfoyle DN Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389 [TBL] [Abstract][Full Text] [Related]
16. The pathogenesis of, and pharmacological treatment for, Canavan disease. Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725 [TBL] [Abstract][Full Text] [Related]
17. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925 [TBL] [Abstract][Full Text] [Related]
18. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. Baslow MH J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786 [TBL] [Abstract][Full Text] [Related]
19. Canavan disease: clinical features and recent advances in research. Hoshino H; Kubota M Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939 [TBL] [Abstract][Full Text] [Related]
20. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice. Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]